Amoxycillin + Clavulanic Acid in pharma franchise in Mizoram

Amoxycillin + Clavulanic Acid in PCD pharma franchise in Chennai

Amoxycillin + Clavulanic Acid in top pharma company in Delhi

Amoxycillin + Clavulanic Acid In pcd pharma supplier in Aurangabad

Amoxycillin + Clavulanic Acid in phama franchise company in India
Amoxycillin + Clavulanic Acid in phama distributor in Nellore

Home/Products /amoxycillin-200mg-clavulanic-acid-28-point-5mg-tablet

Moxyplit CV 228.5 Tablet

Composition : Amoxycillin (200mg) + Clavulanic Acid (28.5mg)

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*10

Price : ₹149/-

Moxyplit CV 228.5 Tablet is a broad-spectrum antibiotic combination that contains Amoxycillin, a penicillin-class antibiotic, and Clavulanic Acid, a beta-lactamase inhibitor. This combination enhances the effectiveness of Amoxycillin, making it more potent against a wider range of bacterial pathogens, including those that produce beta-lactamase, which would normally make the bacteria resistant to Amoxycillin.

Amoxycillin works by inhibiting the growth of bacteria through interference with the bacterial cell wall, ultimately leading to the bacteria’s death. Clavulanic Acid protects Amoxycillin from being broken down by beta-lactamase enzymes produced by resistant bacteria. Together, they provide a powerful treatment for a variety of bacterial infections.

Moxyplit CV 228.5 Tablet is commonly used to treat respiratory infections, urinary tract infections (UTIs), skin infections, and infections of the ear and sinuses. It is also effective for managing infections associated with dental procedures and for more serious infections, including intra-abdominal infections.

Read More

About the Product

Moxyplit CV 228.5 Tablet is a broad-spectrum antibiotic combination that contains Amoxycillin, a penicillin-class antibiotic, and Clavulanic Acid, a beta-lactamase inhibitor. This combination enhances the effectiveness of Amoxycillin, making it more potent against a wider range of bacterial pathogens, including those that produce beta-lactamase, which would normally make the bacteria resistant to Amoxycillin.

Amoxycillin works by inhibiting the growth of bacteria through interference with the bacterial cell wall, ultimately leading to the bacteria’s death. Clavulanic Acid protects Amoxycillin from being broken down by beta-lactamase enzymes produced by resistant bacteria. Together, they provide a powerful treatment for a variety of bacterial infections.

Moxyplit CV 228.5 Tablet is commonly used to treat respiratory infections, urinary tract infections (UTIs), skin infections, and infections of the ear and sinuses. It is also effective for managing infections associated with dental procedures and for more serious infections, including intra-abdominal infections.

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Moxyplit CV 228.5 Tablet Indicated for treating bacterial infections in the ear, nose, throat, lungs, urinary tract, skin, and drug-resistant tuberculosis in children.

Information regarding the use of Moxyplit CV Kid 228.5 Tablet during breastfeeding is not available. Please consult your doctor.

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation